Table 2 Patient characteristics excluding 63 patients with positive surgical margins for RP and their 63 matched pairs for SEED-BT

Age, median (range), years

69 (48–82)

68 (53–79)

0.214

PSA at diagnosis, median (range), ng/mL

8.3 (2.6–18.0)

6.3 (2.9–19.8)

0.253

Clinical stage, number (%)

1.000

 T1c

84 (55.6%)

84 (55.6%)

 T2a–c

67 (44.4%)

67 (44.4%)

Gleason grade, number (%)

0.472

 1

30 (19.9%)

23 (15.2%)

 2

82 (54.3%)

82 (54.3%)

 3

39 (25.8%)

46 (30.5%)

Positive biopsy core rate, number (%)

0.552

  < 34%

92 (60.9%)

97 (64.2%)

  ≥ 34%

59 (39.1%)

54 (35.8%)

Favorable intermediate-risk, number (%)

74 (49.0%)

77 (51.0%)

0.730

Follow-up, median (range), mos

93 (1–153)

92 (11–153)

0.434

Neoadjuvant hormonal therapy yes, number (%)

46 (30.5%)

8 (5.2%)

–

Adjuvant hormonal therapy yes, number (%)

0 (0.0%)

0 (0.0%)

–

Salvage radiotherapy, number (%)

–

23 (15.2%)

–

Positive surgical margin, number (%)

–

0 (0.0%)

–

 Open surgery (n = 79), number (%)

0 (0.0%)

 Laparoscopic surgery (n = 72), number (%)

0 (0.0%)

Combined EBRT, number (%)

39 (25.8%)

–

–

 Favorable intermediate-risk

8 (7.9%)

 Unfavorable intermediate-risk

31 (27.1%)

Prostate D90 at 1 month, Gy

 SEED-BT alone

185.3 (141.0–225.4)

–

 Combined EBRT

121.2 (99.4–180.8)

–

Prostate V100 at 1 month, Gy

 SEED-BT alone

98.0% (80.1–100)

–

 Combined EBRT

96.4% (90.0–99.3)

–

Prostate V150 at 1 month, Gy

 SEED-BT alone

68.2% (23.4–97.3)

–

 Combined EBRT

62.2% (43.6–84.9)

–

BED, Gy2

204.8 (147.9.–284.1)

–